HC Wainwright Issues Optimistic Outlook for ATOS Earnings

Atossa Therapeutics, Inc. (NASDAQ:ATOS) – Stock analysts at HC Wainwright increased their Q3 2025 EPS estimates for Atossa Therapeutics in a research report issued on Tuesday, May 13th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.06) per share for the quarter, up from their prior estimate of ($0.07). HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Atossa Therapeutics’ current full-year earnings is ($0.22) per share. HC Wainwright also issued estimates for Atossa Therapeutics’ FY2025 earnings at ($0.24) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.26) EPS, FY2028 earnings at ($0.21) EPS and FY2029 earnings at ($0.16) EPS.

Atossa Therapeutics (NASDAQ:ATOS) last issued its earnings results on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01.

Separately, Ascendiant Capital Markets upped their price objective on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a “buy” rating in a research note on Monday, April 21st.

Atossa Therapeutics Price Performance

NASDAQ ATOS opened at $0.97 on Friday. Atossa Therapeutics has a 1 year low of $0.55 and a 1 year high of $1.71. The company has a market capitalization of $125.31 million, a PE ratio of -4.41 and a beta of 1.01. The company has a fifty day moving average of $0.73 and a two-hundred day moving average of $0.92.

Institutional Investors Weigh In On Atossa Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Gallagher Capital Advisors LLC purchased a new stake in shares of Atossa Therapeutics in the fourth quarter valued at about $25,000. Millennium Management LLC purchased a new stake in shares of Atossa Therapeutics in the fourth quarter valued at about $28,000. Two Sigma Advisers LP raised its holdings in shares of Atossa Therapeutics by 214.1% in the fourth quarter. Two Sigma Advisers LP now owns 42,400 shares of the company’s stock valued at $40,000 after buying an additional 28,900 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Atossa Therapeutics by 224.0% in the fourth quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock valued at $59,000 after buying an additional 43,449 shares during the last quarter. Finally, Wells Fargo & Company MN raised its holdings in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after buying an additional 16,853 shares during the last quarter. 12.74% of the stock is owned by hedge funds and other institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.